Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations-Reference-Cited by-同舟云学术

Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations

Published:2021-07 Issue:7 Volume:14 Page:101102
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Izumi Motohiro,Sawa Kenji,Oyanagi Jun,Noura Ikue,Fukui Mitsuru,Ogawa Koichi,Matsumoto Yoshiya,Tani Yoko,Suzumura Tomohiro^ORCID,Watanabe Tetsuya,Kaneda Hiroyasu,Mitsuoka Shigeki,Asai Kazuhisa^ORCID,Nishiyama Noritoshi,Ohsawa Masahiko,Yamamoto Nobuyuki,Koh Yasuhiro^ORCID,Kawaguchi Tomoya

Funder

Japan Society for the Promotion of Science

Osaka Medical Research Foundation for Intractable Diseases

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic and transcriptomic significance of multiple primary lung cancers detected by next-generation sequencing in clinical settings;Carcinogenesis;2024-05-02

2. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer;Cancer Immunology, Immunotherapy;2024-04-26

3. Bilateral synchronous double primary lung cancer: A case report;Clinical Case Reports;2024-04

4. A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL);Frontiers in Oncology;2024-03-27

5. Towards the molecular era of discriminating multiple lung cancers;eBioMedicine;2023-04